| Patent application number | Description | Published |
|---|
| 20080262107 | Pharmaceutical Compositions With Enhanced Performance - Disclosed are polymers of hydroxypropyl methyl cellulose acetate succinate (HPMCAS) and hydroxypropyl methyl cellulose acetate (HPMCA) with unique degrees of substitution of hydroxypropoxy, methoxy, acetyl, and succinoyl groups. When used in making compositions comprising a low-solubility drug and such polymers, the polymers provide enhanced aqueous concentrations and/or improved physical stability. | 10-23-2008 |
| 20090118328 | Pharmaceutical Compositions Of Cholesteryl Ester Transfer Protein Inhibitors And Hmg-Coa Reductase - A solid amorphous dispersion comprises a cholesteryl ester transfer protein (CETP) inhibitor, an inhibitor of 3-hydroxy-3-methylglutaryl-conenzyme A reductase (HMG-CoA reductase inhibitor), and a concentration enhancing polymer. At least a major portion of the CETP inhibitor in the dispersion is amorphous. The solid amorphous dispersion provides concentration-enhancement of the CETP inhibitor when administered to an aqueous use environment. | 05-07-2009 |
| 20090142401 | Multiparticulates comprising low-solubility drugs and carriers that result in rapid drug release - Multiparticulates of low-solubility drugs and carriers that result in rapid release of the drug are disclosed. | 06-04-2009 |
| 20100003331 | SUSTAINED RELEASE DOSAGE FORMS OF ZIPRASIDONE - A sustained release solid oral dosage form for treatment of a psychotic disorder, for example schizophrenia, in a mammal is provided, which oral dosage form comprises ziprasidone in an amount effective in treating said psychotic disorder and a pharmaceutically acceptable carrier. | 01-07-2010 |
| 20100028440 | DRYING OF DRUG-CONTAINING PARTICLES - A secondary drying process is disclosed for removing residual solvent from drug-containing particles that have been formed by solvent-based processes. | 02-04-2010 |
| 20100029667 | Spray dried formulation - Pharmaceutical compositions comprising a poorly water soluble ionizable drug, a cationic species and a dispersion polymer are disclosed, together with a process for forming the compositions. The neutral form of the drug has (i) a solubility of less than 1 mg/ml, in aqueous solution at a pH between 6 and 7, (ii) a solubility of less than 20 mg/mL in a volatile organic solvent, and (iii) an acidic pKa value of greater than 5. At least 90 wt % of the drug in the solid dispersion being in a non-crystalline form. The drug, the cationic species, and the dispersion polymer constitute at least 80 wt % of the solid dispersion. | 02-04-2010 |
| 20110002989 | METHODS, DOSAGE FORMS AND KITS FOR ADMINISTERING ZIPRASIDONE WITHOUT FOOD - The present invention provides methods, dosage forms and kits for treating with an effective amount of ziprasidone a CNS disorder in a human when the human is in a fasted state. In one embodiment, the invention relates to a method for treating a CNS disorder in a human, which method comprises administering to the human in a fasted state, a solid oral dosage form comprising an amount of ziprasidone effective to treat said CNS disorder, wherein the area under the serum concentration versus time curve (AUC | 01-06-2011 |
| 20110027372 | MULTIPARTICULATES COMPRISING LOW-SOLUBILITY DRUGS AND CARRIERS THAT RESULT IN RAPID DRUG RELEASE - Multiparticulates of low-solubility drugs and carriers that result in rapid release of the drug are disclosed. | 02-03-2011 |
